Expertise in
4
conditions

Dr. Jianqing Lin

Hematology | Oncology | Internal Medicine
Sentara Rmh Medical Center Oncology
2010 Health Campus Dr, 
Harrisonburg, VA 
Expertise in
4
conditions
Sentara Rmh Medical Center Oncology
2010 Health Campus Dr, 
Harrisonburg, VA 

Overview

Jianqing Lin is a Hematologist and an Oncologist practicing medicine in Harrisonburg, Virginia.

Dr. Lin is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Muscle Invasive Bladder Cancer, Deep Vein Thrombosis, Non-Muscle Invasive Bladder Cancer, and Thrombocytopenia.

Dr. Lin is board certified in American Board Of Internal Medicine - Medical Oncology - 2027 and American Board Of Internal Medicine - Internal Medicine - 2027. He is actively involved in clinical research, co-authoring 38 peer reviewed articles and participating in 13 clinical trials.

Graduate Institution

MD - Zhejiang University School Of Medicine

Residency

Carney Hospital

Specialties

Hematology
Oncology
Internal Medicine

Licenses

Specialist in MD

Board Certifications

American Board Of Internal Medicine - Medical Oncology - 2027
American Board Of Internal Medicine - Internal Medicine - 2027

Fellowships

Johns Hopkins University School of Medicine - 2009

Hospital Affiliations

Sentara Rmh Medical Center
University Of Virginia Medical Center
Page Memorial Hospital, Inc
Shenandoah Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Sentara Rmh Medical Center Oncology
2010 Health Campus Dr, Harrisonburg, VA 22801
Other Locations
Sentara Hematology & Oncology Specialists
2008 Health Campus Drive, Harrisonburg, VA 22801

Additional Areas of Focus

Dr. Lin has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Enrollment Status: Terminated
Publish Date: April 22, 2026
Intervention Type: Procedure, Other, Drug
Study Drugs: Enzalutamide, Ribociclib
Study Phase: Phase 1/Phase 2
A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 16, 2026
Intervention Type: Drug
Study Drugs: Sunitinib, Valproic Acid
Study Phase: Phase 2
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2026
Intervention Type: Other, Drug
Study Drugs: Enzalutamide, Rucaparib Camsylate, Leuprolide Acetate, Goserelin Acetate, Degarelix
Study Phase: Phase 3
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Radiation
Study Drugs: Enzalutamide, Goserelin Acetate, Leuprolide Acetate
Study Phase: Phase 1
Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Radiation, Other, Procedure
Study Phase: Phase 1
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
Phase I Trial of Weekly Cabazitaxel With Concurrent Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy for the Treatment of Locally Advanced High Risk Adenocarcinoma of the Prostate
Phase I Trial of Weekly Cabazitaxel With Concurrent Intensity Modulated Radiation Therapy and Androgen Deprivation Therapy for the Treatment of Locally Advanced High Risk Adenocarcinoma of the Prostate
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Drug, Genetic, Radiation
Study Drugs: Cabazitaxel, Bicalutamide, Luliberin
Study Phase: Phase 1
View 9 Less Clinical Trials

38 Total Publications

Tumor microenvironment-responsive cerium oxide nanozyme coated ZIF-8 nanoplatform with ICG encapsulation for precise breast cancer surgery and efficacious synergistic suppression.
Tumor microenvironment-responsive cerium oxide nanozyme coated ZIF-8 nanoplatform with ICG encapsulation for precise breast cancer surgery and efficacious synergistic suppression.
Journal: Materials today. Bio
Published: September 04, 2025
Similar Doctors
Expertise in
21
conditions
Dr. Benjamin W. Purow
Hematology | Oncology
Expertise in
21
conditions
Dr. Benjamin W. Purow
Hematology | Oncology
Referral may be required

UVA Health Neuro Oncology

1240 Lee St Fl 3, 
Charlottesville, VA 
 (33.7 miles away)
434-924-9333
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Benjamin Purow is a Hematologist and an Oncologist practicing medicine in Charlottesville, Virginia. Dr. Purow is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Purow is currently accepting new patients.

Expertise in
37
conditions
Dr. Brian E. Robinson
Hematology | Oncology
Expertise in
37
conditions
Dr. Brian E. Robinson
Hematology | Oncology
Referral may be required

Shenandoah Valley Radiation Oncology Associates PC

2008 Health Campus Dr, 
Rockingham, VA 
 (1.2 miles away)
540-689-7000
Languages Spoken:
English

Brian Robinson is a Hematologist and an Oncologist practicing medicine in Rockingham, Virginia. Dr. Robinson is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Colorectal Cancer, Inflammatory Breast Cancer, and Bone Marrow Aspiration.

Expertise in
3
conditions
Dr. Kimberly P. Dunsmore
Hematology | Oncology
Expertise in
3
conditions
Dr. Kimberly P. Dunsmore
Hematology | Oncology
Referral may be required

UVA Health Heart And Vascular Center Fontaine

500 Ray C Hunt Dr, 
Charlottesville, VA 
 (32.4 miles away)
434-924-0000
Languages Spoken:
English

Kimberly Dunsmore is a Hematologist and an Oncologist practicing medicine in Charlottesville, Virginia. Dr. Dunsmore is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Adult T-Cell Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia, and RUNX1 Familial Platelet Disorder.

Frequently Asked Questions about Dr. Jianqing Lin

How do I make an appointment with Dr. Jianqing Lin?

You can book an appointment with Dr. Jianqing Lin by calling their office at 540-689-7000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jianqing Lin a top-rated expert for Muscle Invasive Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jianqing Lin is classified as an Advanced expert for Muscle Invasive Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jianqing Lin specialize in?

While Dr. Jianqing Lin is a Hematology, they have specific expertise in Muscle Invasive Bladder Cancer, Deep Vein Thrombosis, and Non-Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jianqing Lin participate in research or clinical trials?

Yes. Dr. Jianqing Lin has published 38 articles and abstracts on conditions like Muscle Invasive Bladder Cancer. You can view a list of Dr. Jianqing Lin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jianqing Lin accept my insurance?

Dr. Jianqing Lin accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 540-689-7000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lin's expertise for a condition
ConditionClose
      View All 55 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile